Fox Chase Cancer Center, part of Philadelphia-based Temple Health, has held National Cancer Institute-designated comprehensive cancer center status for more than 50 years, one of the original centers so designated. Its scientists’ 1959 discovery of the “Philadelphia Chromosome” laid the groundwork for the drug Gleevec and the field of cancer genetics. In 2025, Fox Chase earned its strongest cancer center support grant score in more than two decades, published 692 scientific articles, enrolled patients in 207 clinical trials and drew more than $78 million across 435 active funded projects. The center also became the first hospital in Pennsylvania to achieve six Magnet recognition program renewals for nursing excellence, most recently in 2023, and its Blood Cancer and Cellular Therapy Institute recently surpassed 3,000 bone marrow transplants. Fox Chase, per Pennsylvania Health Care Cost Containment Council data, is now the state’s highest-volume center for bladder and kidney cancer surgery. In 2025, Fox Chase was named Philadelphia’s first comprehensive radiopharmaceutical therapy center of excellence, and the center opened a nearly $4 million oncology satellite pharmacy, funded partly by a $1.5 million grant, that triples its capacity to mix chemotherapy infusions and can prepare more than 500 treatments daily. Backed by more than $175 million in recent clinical and research infrastructure investment, Fox Chase continues to expand programs including outpatient CAR T-cell therapy, a third robotic surgery platform and a new advanced treatment center.
